Oncolytic virus and anti-4-1BB combination therapy elicits strong antitumor immunity against established cancer

Cancer Research

Volumn 72, Issue 7, 2012, Pages 1651-1660

  John, Liza B ^a   Howland, Linda J ^a   Flynn, Jacqueline K ^a   West, Alison C ^a   Devaud, Christel ^a   Duong, Connie P ^a   Stewart, Trina J ^a   Westwood, Jenny A ^a   Guo, Z Sheng ^d   Bartlett, David L ^d   Smyth, Mark J ^a,b,c   Kershaw, Michael H ^a,b,c   Darcy, Phillip K ^a,b,c  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c MONASH UNIVERSITY   (Australia)

^d UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD11B ANTIGEN; CD137 ANTIGEN; GAMMA INTERFERON; GLYCOPROTEIN P 15095; ONCOLYTIC VIRUS; VIROTHERAPY AGENT;

ADAPTIVE IMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BONE MARROW CELL; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DEATH; CELL VIABILITY; COLON CANCER; CONTROLLED STUDY; DISTANT METASTASIS; DRUG CYTOTOXICITY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG RESPONSE; EFFECTOR CELL; HOST RANGE; IMMUNE RESPONSE; IMMUNOGENICITY; INNATE IMMUNITY; LUNG METASTASIS; LYMPHOCYTIC INFILTRATION; METASTASIS POTENTIAL; MOUSE; NATURAL KILLER T CELL; NEUTROPHIL; NONHUMAN; ONCOLYTIC VIROTHERAPY; PRIORITY JOURNAL; SUBCUTANEOUS TISSUE TUMOR; TUMOR IMMUNITY; VACCINIA VIRUS;

ADAPTIVE IMMUNITY; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD137; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; IMMUNITY, INNATE; INTERFERON-GAMMA; LYMPH NODES; MICE; MICE, INBRED BALB C; NEOPLASMS, EXPERIMENTAL; ONCOLYTIC VIROTHERAPY; VACCINIA VIRUS;

EID: 84858762241     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-11-2788     Document Type: Article

References (49)

1. Breitbach CJ, Reid T, Burke J, Bell JC, Kirn DH. Navigating the clinical development landscape for oncolytic viruses and other cancer therapeutics: No shortcuts on the road to approval. Cytokine Growth Factor Rev 2010;21:85-9.
2. Bell J. Oncolytic viruses: an approved product on the horizon? Mol Ther 2010;18:233-4.
3. Guo ZS, Thorne SH, Bartlett DL. Oncolytic virotherapy: molecular targets in tumor-selective replication and carrier cell-mediated delivery of oncolytic viruses. Biochim Biophys Acta 2008;1785:217-31.
4. Sinkovics JG, Horvath JC. Natural and genetically engineered viral agents for oncolysis and gene therapy of human cancers. Arch Immunol Ther Exp (Warsz) 2008;56 Suppl 1:3s-59s.
5. McCart JA, Ward JM, Lee J, Hu Y, Alexander HR, Libutti SK, et al. Systemic cancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes. Cancer Res 2001;61:8751-7. (Pubitemid 34013887)
6. Rowan K. Oncolytic viruses move forward in clinical trials. J Natl Cancer Inst 2010;102:590-5.
7. Grote D, Cattaneo R, Fielding A. Neutrophils contribute to the measles virus-induced antitumor effect: enhancement by granulocyte macrophage colony-stimulating factor expression. Cancer Res 2003;63: 6463-8. (Pubitemid 37255198)
8. Breitbach CJ, Paterson JM, Lemay CG, Falls TJ, McGuire A, Parato KA, et al. Targeted inflammation during oncolytic virus therapy severely compromises tumor blood flow. Mol Ther 2007;15:1686-93. (Pubitemid 47289013)
9. Melero I, Hervas-Stubbs S, Glennie M, Pardoll DM, Chen L. Immunostimulatory monoclonal antibodies for cancer therapy. Nat Rev Cancer 2007;7:95-106. (Pubitemid 46160986)
10. Melero I, Shuford W, Newby S, Aruffo A, Ledbetter J, Hellström K, et al. Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nat Med 1997;3:682-5. (Pubitemid 27264981)
11. Kim JA, Averbook BJ, Chambers K, Rothchild K, Kjaergaard J, Papay R, et al. Divergent effects of 4-1BB antibodies on antitumor immunity and on tumor-reactive T-cell generation. Cancer Res 2001;61:2031-7. (Pubitemid 32692024)
12. Stewart TJ, Abrams SI. Altered immune function during long-term host-tumor interactions can be modulated to retard autochthonous neoplastic growth. J Immunol 2007;179:2851-9.
13. Guo ZS, Naik A, O'Malley ME, Popovic P, Demarco R, Hu Y, et al. The enhanced tumor selectivity of an oncolytic vaccinia lacking the host range and antiapoptosis genes SPI-1 and SPI-2. Cancer Res 2005;65:9991-8. (Pubitemid 41541480)
14. Vanderplasschen A, Mathew E, Hollinshead M, Sim RB, Smith GL. Extracellular enveloped vaccinia virus is resistant to complement because of incorporation of host complement control proteins into its envelope. Proc Natl Acad Sci U S A 1998;95:7544-9. (Pubitemid 28293289)
15. Mosmann T. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J Immunol Methods 1983;65:55-63. (Pubitemid 14203433)
16. Han J, Zhong CQ, Zhang DW. Programmed necrosis: backup to and competitor with apoptosis in the immune system. Nat Immunol 2011;12:1143-9.
17. Park BH, Hwang T, Liu TC, Sze DY, Kim JS, Kwon HC, et al. Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial. Lancet Oncol 2008;9:533-42.
18. Zhang Q, Yu YA, Wang E, Chen N, Danner RL, Munson PJ, et al. Eradication of solid human breast tumors in nude mice with an intravenously injected light-emitting oncolytic vaccinia virus. Cancer Res 2007;67:10038-46. (Pubitemid 47621255)
19. Grote D, Russell SJ, Cornu TI, Cattaneo R, Vile R, Poland GA, et al. Live attenuated measles virus induces regression of human lymphoma xenografts in immunodeficient mice. Blood 2001;97: 3746-54.
20. Stojdl DF, Lichty BD, tenOever BR, Paterson JM, Power AT, Knowles S, et al. VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell 2003;4: 263-75. (Pubitemid 37329791)
21. Phuangsab A, Lorence RM, Reichard KW, Peeples ME, Walter RJ. Newcastle disease virus therapy of human tumor xenografts: antitumor effects of local or systemic administration. Cancer Lett 2001;172: 27-36. (Pubitemid 32823469)
22. Norman KL, Coffey MC, Hirasawa K, Demetrick DJ, Nishikawa SG, DiFrancesco LM, et al. Reovirus oncolysis of human breast cancer. Hum Gene Ther 2002;13:641-52. (Pubitemid 34264314)
23. De Palma M, Venneri MA, Naldini L. In vivo targeting of tumor endothelial cells by systemic delivery of lentiviral vectors. Hum Gene Ther 2003;14:1193-206. (Pubitemid 36930408)
24. Fu X, Zhang X. Potent systemic antitumor activity from an oncolytic herpes simplex virus of syncytial phenotype. Cancer Res 2002;62: 2306-12. (Pubitemid 34411709)
25. Boisgerault N, Tangy F, Gregoire M. New perspectives in cancer virotherapy: bringing the immune system into play. Immunotherapy 2010;2:185-99.
26. Guo ZS, Parimi V, O'Malley ME, Thirunavukarasu P, Sathaiah M, Austin F, et al. The combination of immunosuppression and carrier cells significantly enhances the efficacy of oncolytic poxvirus in the pre-immunized host. Gene Ther 2010;17:1465-75.
27. Westwood JA, Haynes NM, Sharkey J, McLaughlin N, Pegram HJ, Schwendener RA, et al. Toll-like receptor triggering and T-cell costimulation induce potent antitumor immunity in mice. Clin Cancer Res 2009;15:7624-33.
28. Chen L, Huang TG, Meseck M, Mandeli J, Fallon J, Woo SL. Rejection of metastatic 4T1 breast cancer by attenuation of Treg cells in combination with immune stimulation. Mol Ther 2007;15:2194-202. (Pubitemid 350148937)
29. Kim HS, Kim-Schulze S, Kim DW, Kaufman HL. Host lymphodepletion enhances the therapeutic activity of an oncolytic vaccinia virus expressing 4-1BB ligand. Cancer Res 2009;69:8516-25.
30. Kaufman H, DeRaffele G, Mitcham J, Moroziewicz D, Cohen S, Hurst- Wicker K, et al. Targeting the local tumor microenvironment with vaccinia virus expressing B7.1 for the treatment of melanoma. J Clin Invest 2005;115:1903-12. (Pubitemid 40979730)
31. Kaufman H,Cohen S, Cheung K, DeRaffele G, Mitcham J, Moroziewicz D, et al. Local delivery of vaccinia virus expressing multiple costimulatory molecules for the treatment of established tumors. Hum Gene Ther 2006;17:239-44. (Pubitemid 43263093)
32. Fecker LF, Ruckert S, Kurbanov BM, Schmude M, Stockfleth E, Fechner H, et al. Efficient melanoma cell killing and reduced melanoma growth in mice by a selective replicating adenovirus armed with tumor necrosis factor-related apoptosis-inducing ligand. Hum Gene Ther 2011;22:405-17.
33. Wilcox RA, Chapoval AI, Gorski KS, Otsuji M, Shin T, Flies DB, et al. Cutting edge: Expression of functional CD137 receptor by dendritic cells. J Immunol 2002;168:4262-7. (Pubitemid 34441322)
34. Haynes NM, Trapani JA, Teng MWL, Jackson JT, Cerruti L, Jane SM, et al. Rejection of syngeneic colon carcinoma by CTLs expressing single-chain antibody receptors codelivering CD28 costimulation. J Immunol 2002;169:5780-6. (Pubitemid 35291680)
35. Boehm U, Klamp T, Groot M, Howard JC. Cellular responses to interferon-gamma. Annu Rev Immunol 1997;15:749-95.
36. Bohm W, Thoma S, Leithauser F, Moller P, Schirmbeck R, Reimann J. T cell-mediated, IFN-gamma-facilitated rejection of murine B16 melanomas. J Immunol 1998;161:897-908. (Pubitemid 28323555)
37. Hawley RG, Berger LC. Growth control mechanisms in multiple myeloma. Leuk Lymphoma 1998;29:465-75. (Pubitemid 28288712)
38. Beatty G, Paterson Y. Regulation of tumor growth by IFN-γ in cancer immunotherapy. Immunol Res 2001;24:201-10. (Pubitemid 32897079)
39. Nakajima C, Uekusa Y, Iwasaki M, Yamaguchi N, Mukai T, Gao P, et al. A role of interferon-gamma in tumor immunity. Cancer Res 2001;61:3399-405.
40. Coughlin CM, Salhany KE, Gee MS, LaTemple DC, Kotenko S, Ma X, et al. Tumor cell responses to IFN-gamma affect tumorigenicity and response to IL-12 therapy and antiangiogenesis. Immunity 1998;9: 25-34. (Pubitemid 28361292)
41. Beatty GL, Paterson Y. IFN-gamma-dependent inhibition of tumor angiogenesis by tumor-infiltrating CD4+ T cells requires tumor responsiveness to IFN-gamma. J Immunol 2001;166:2276-82. (Pubitemid 32173458)
42. Lopez A, Strath M, Sanderson C. Differentiation antigens on mouse eosinophils and neutrophils identified by monoclonal antibodies. Br J Haematol 1984;57:489-94. (Pubitemid 14082099)
43. Gregory AD, McGarry Houghton A. Tumor-associated neutrophils: New targets for cancer therapy. Cancer Res 2011;71:2411-6.
44. Nathan C. Neutrophils and immunity: challenges and opportunities. Nat Rev Immunol 2006;6:173-82. (Pubitemid 43290987)
45. Smith JA. Neutrophils, host defense, and inflammation: a double-edged sword. J Leuk Biol 1994;56:672-86.
46. Pham CTN. Neutrophil serine proteases: specific regulators of inflammation. Nat Rev Immunol 2006;6:541-50. (Pubitemid 43980526)
47. Fridlender ZG, Sun J, Kim S, Kapoor V, Cheng G, Ling L, et al. Polarization of tumor-associated neutrophil phenotype by TGF-beta: N1 versus N2 TAN. Cancer cell 2009;16:183-94.
48. Croft M. Control of immunity by the TNFR-related molecule OX40 (CD134). Annu Rev Immunol 2010;28:57-78.
49. Heinisch IV, Daigle I, Knöpfli B, Simon HU. CD137 activation abrogates granulocyte-macrophage colony-stimulating factor-mediated anti-apoptosis in neutrophils. Eur J Immunol 2000;30: 3441-6. (Pubitemid 32005215)